Erythropoietin Stimulates Tumor Growth <i>via</i> EphB4

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

SUMMARY

While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo’s effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 101130617

Journal ID (pubmed-jr-id): 29778

Journal ID (nlm-ta): Cancer Cell

Journal ID (iso-abbrev): Cancer Cell

Title: Cancer cell

ISSN (Print): 1535-6108

ISSN (Electronic): 1878-3686

Publication date Nihms-submitted: 26 September 2015

Publication date (Electronic): 17 October 2015

Publication date (Print): 9 November 2015

Publication date PMC-release: 09 November 2016

Volume: 28

Issue: 5

Pages: 610-622

Affiliations

[1 ]Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584

[2 ]Department of Surgery, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico

[3 ]University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico

[4 ]Department of Surgical Oncology, Chapel Hill, NC

[5 ]Department of Benign Hematology, Chapel Hill, NC

[6 ]Division of Hematology/Oncology, Chapel Hill, NC

[7 ]MolecularHealth GmbH, Heidelberg, Germany

[8 ]Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center 77030, USA

[9 ]Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center 77030, USA

[10 ]Department of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030

[11 ]Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030

[12 ]Sygnis AG, Germany

[13 ]Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

[14 ]Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

[15 ]Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

[16 ]Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

Author notes

Correspondence: Anil K. Sood, M.D., Departments of Gynecologic Oncology and Cancer Biology, U.T. M. D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, P.O. Box 301439 Houston, TX 77030-1439 713-745-5266 (phone), 713-792-7586 (fax), asood@ 123456mdanderson.org

[*]

These authors contributed equally to this manuscript.

Article

Accession ID: PMC4643364 Pmcid ID: PMC4643364 Pmc-uid ID: 4643364 Manuscript ID: nihpa725533

DOI: 10.1016/j.ccell.2015.09.008

PMC ID: 4643364

PubMed ID: 26481148

SO-VID: 4f8bb305-8e9e-48db-989f-7026f0122d1f

History

Comments

Comment on this article

scite_

Cited by 38

See all cited by

Erythropoietin Stimulates Tumor Growth via EphB4

Read this article at